Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) released its earnings results on Monday. The company reported ($0.01) EPS for the quarter, Zacks reports. The company had revenue of $0.59 million during the quarter.
Guided Therapeutics Stock Performance
Shares of Guided Therapeutics stock traded down $0.01 on Wednesday, reaching $0.22. 8,246 shares of the company’s stock were exchanged, compared to its average volume of 16,659. The company has a market capitalization of $20.40 million, a P/E ratio of -4.41 and a beta of 0.57. Guided Therapeutics has a 52 week low of $0.06 and a 52 week high of $0.54. The firm’s 50-day moving average is $0.34 and its two-hundred day moving average is $0.31.
About Guided Therapeutics
Guided Therapeutics, Inc is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.
The company secured 510(k) clearance from the U.S.
Featured Stories
Receive News & Ratings for Guided Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guided Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
